David C Taussig

Summary

Affiliation: Queen Mary
Country: UK

Publications

  1. pmc Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction
    David C Taussig
    Cancer Research UK Medical Oncology Unit, St Bartholomew s Hospital, Queen Mary University of London, London
    Blood 115:1976-84. 2010
  2. doi request reprint Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
    David C Taussig
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Blood 112:568-75. 2008
  3. doi request reprint Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo
    Farideh Miraki-Moud
    Centre for Haemato Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
    Blood 125:4060-8. 2015

Collaborators

  • Dominique Bonnet
  • Fernando Anjos-Afonso
  • Farideh Miraki-Moud
  • Katharine A Hodby
  • Essam Ghazaly
  • John S Bomalaski
  • Konstantinos Liapis
  • Peter W Szlosarek
  • Jamie Cavenagh
  • Linda Ariza-McNaughton
  • Fareeda Sohrabi
  • John G Gribben
  • Marianne Grantham
  • Andrew Clear

Detail Information

Publications3

  1. pmc Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction
    David C Taussig
    Cancer Research UK Medical Oncology Unit, St Bartholomew s Hospital, Queen Mary University of London, London
    Blood 115:1976-84. 2010
    ..This feature of LICs may make them particularly difficult to eradicate using therapies targeted against surface antigens...
  2. doi request reprint Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
    David C Taussig
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Blood 112:568-75. 2008
    ..More importantly, the work suggests that there is greater variation in the phenotypes of leukemia-initiating cells than previously suggested...
  3. doi request reprint Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo
    Farideh Miraki-Moud
    Centre for Haemato Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
    Blood 125:4060-8. 2015
    ..Our data show that arginine deprivation is a reasonable strategy in AML that paves the way for clinical trials. ..